News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
Phase III Trials of Novartis' Remibrutinib Successfully Achieve Primary Endpoints and Indicate Swift Symptom Management in Chronic Spontaneous Urticaria
Wednesday, August 09, 2023Novartis has revealed positive outcomes from two Phase III trials REMIX and REMIX which assessed the effectiveness of remibrutinib a Brutons tyrosine kinase BTK inhibitor in managing chronic spontaneous urticaria CSU patients who exhibit insufficient...
Biophytis Receives Positive Evaluation for Phase 3 SARA-31 Trial Addressing Sarcopenia in Europe
Tuesday, August 08, 2023Biophytis SA a biotechnology company listed on Nasdaq CM BPTS and Euronext Growth Paris ALBPS has received favorable feedback from Belgian authorities to initiate the innovative SARA initiative
Bavarian Nordic Releases Positive Phase 3 Topline Findings for Chikungunya Virus Vaccine in Adults and Adolescents
Monday, August 07, 2023Bavarian Nordic AS OMX BAVA has recently unveiled positive topline results from a Phase clinical trial NCT for their chikungunya virus vaccine candidate CHIKV VLP PXVX
Evox Therapeutics Teams Up to Progress Next-Generation Exosome-Mediated AAV Gene Therapy for Heart Disease Treatment
Saturday, August 05, 2023Evox Therapeutics Ltd a prominent biotech company specializing in exosome therapeutics has recently announced a research collaboration and option agreement with the Icahn School of Medicine at Mount Sinai Icahn Mount Sinai in New York NY
Askbio Commences Phase 1/phase 2 Clinical Study of AB-1003 Gene Therapy for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
Friday, August 04, 2023Asklepios BioPharmaceutical Inc AskBio a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG
Neurobo Pharmaceuticals Receives First Site IRB Approval for a Phase 2a Clinical Trial Evaluating DA-1241 as a Potential Treatment for NASH
Friday, August 04, 2023NeuroBo Pharmaceuticals Inc Nasdaq NRBO a biotechnology company in the clinicalstage is dedicated to addressing cardiometabolic diseases
IGC Pharma Extends Phase 2 Trial of IGC-AD1 to Include Collaboration with the University of Puerto Rico
Thursday, August 03, 2023IGC Pharma Inc NYSE American IGC announced the addition of a trial site at the University of Puerto Rico network to expand its ongoing Phase clinical trial investigating IGCAD the companys lead drug asset
Cybin Commences Dosing of Last Cohort in Phase 2 Trial of CYB003 for Major Depressive Disorder
Thursday, August 03, 2023Cybin Inc NYSE American CYBN NEO CYBN is making significant strides in its commitment to revolutionize mental healthcare through the development of innovative psychedelicbased treatment options
Cadrenal Therapeutics Expands the Scope of Tecarfarin to Incorporate Patients With Implanted Medical Devices for Heart Diseases
Wednesday, August 02, 2023Cadrenal Therapeutics Inc Nasdaq CVKD a biopharmaceutical company has recently announced its plan to expand the focus of its latestage novel oral anticoagulant tecarfarin
Entrada Therapeutics Receives Green Light for Phase 1 Clinical Trial of ENTR-601-44 in the UK to Explore Treatment Potential for Duchenne Muscular Dystrophy
Wednesday, August 02, 2023Entrada Therapeutics Inc Nasdaq TRDA is a biopharmaceutical company with a mission to revolutionize patient lives by introducing intracellular Endosomal Escape Vehicle EEVtherapeutics as a new category of medicines
